Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8178693 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2024
(a month ago) | |
US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8193229 | ARRAY BIOPHARMA INC | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
US8513293 | ARRAY BIOPHARMA INC | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar, 2023
(1 year, 1 month ago) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(7 years from now) | |
US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) |
Mektovi is owned by Array Biopharma Inc.
Mektovi contains Binimetinib.
Mektovi has a total of 11 drug patents out of which 4 drug patents have expired.
Expired drug patents of Mektovi are:
Mektovi was authorised for market use on 27 June, 2018.
Mektovi is available in tablet;oral dosage forms.
Mektovi can be used as indicated in combination with encorafenib for the treatment of melanoma with a braf mutation, indicated in combination with encorafenib for the treatment of melanoma, mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-approved test, method of treating melanoma, treatment of melanoma with a braf mutation.
Drug patent challenges can be filed against Mektovi from 27 June, 2022.
The generics of Mektovi are possible to be released after 18 October, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
New Indication(I-928) | Oct 11, 2026 |
New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of pati...
Dosage: TABLET;ORAL